Matrigel alters the pathophysiology of orthotopic human breast adenocarcinoma xenografts with implications for nanomedicine evaluation

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 9, Issue 6, 2013, Pages 795-805

  Shuhendler, Adam J ^a   Prasad, Preethy ^a   Cai, Ping ^a   Hui, Kelvin K W ^a   Henderson, Jeffrey T ^a   Rauth, Andrew M ^b,c   Wu, Xiao Yu ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Altered pathophysiology; Enhanced tumor perfusion; Lymphangiogenesis; Matrigel; Nanoparticle retention; Orthotopic breast adenocarcinoma xenografts

Indexed keywords

LYMPHANGIOGENESIS; MATRIGEL; ORTHOTOPIC; PATHOPHYSIOLOGY; TUMOR PERFUSION;

BIOLOGICAL MATERIALS; BIOLOGICAL MEMBRANES; BLOOD VESSELS; MAMMALS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES;

TUMORS;

FATTY ACID ESTER; MATRIGEL; NANOPARTICLE; QUANTUM DOT; COLLAGEN; DRUG COMBINATION; LAMININ; PROTEOGLYCAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST ADENOCARCINOMA; CONTROLLED STUDY; DRUG RETENTION; HUMAN; HUMAN CELL; LYMPH FLOW; MORPHOLOGY; MOUSE; NANOMEDICINE; NONHUMAN; PATHOPHYSIOLOGY; TUMOR BLOOD FLOW; TUMOR GROWTH; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; BREAST TUMOR; CHEMISTRY; DRUG COMBINATION; EVALUATION STUDY; FEMALE; METABOLISM; TUMOR CELL LINE; XENOGRAFT;

RODENTIA;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; COLLAGEN; DRUG COMBINATIONS; FEMALE; HETEROGRAFTS; HUMANS; LAMININ; MICE; NANOMEDICINE; NANOPARTICLES; PROTEOGLYCANS;

EID: 84880753753     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.01.005     Document Type: Article

References (31)

1. Benton G., Kleinman H.K., George J., Arnaoutova I. Multiple uses of basement membrane-like matrix (BME/Matrigel) in vitro and in vivo with cancer cells. Int J Cancer 2010.
2. Fridman R., Kibbey M.C., Royce L.S., Zain M., Sweeney M., Jicha D.L., et al. Enhanced tumor growth of both primary and established human and murine tumor cells in athymic mice after coinjection with Matrigel. J Natl Cancer Inst 1991, 83:769-774.
3. Kleinman H.K., Martin G.R. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005, 15:378-386.
4. Liotta L.A., Rao C.N., Wewer U.M. Biochemical interactions of tumor cells with the basement membrane. Annu Rev Biochem 1986, 55:1037-1057.
5. Terranova V.P., Williams J.E., Liotta L.A., Martin G.R. Modulation of the metastatic activity of melanoma cells by laminin and fibronectin. Science 1984, 226:982-985.
6. Vaillant F., Lindeman G.J., Visvader J.E. Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays?. Breast Cancer Res 2011, 13:108.
7. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 20103-53.
8. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000, 65:271-284.
9. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001, 41:189-207.
10. Wang M., Thanou M. Targeting nanoparticles to cancer. Pharmacol Res 2010, 62:90-99.
11. Kim W.H., Jun S.H., Kibbey M.C., Thompson E.W., Kleinman H.K. Expression of beta 1 integrin in laminin-adhesion-selected human colon cancer cell lines of varying tumorigenicity. Invasion Metastasis 1994, 14:147-155.
12. Huang N.F., Yu J., Sievers R., Li S., Lee R.J. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng 2005, 11:1860-1866.
13. Ou L., Li W., Zhang Y., Wang W., Liu J., Sorg H., et al. Intracardiac injection of matrigel induces stem cell recruitment and improves cardiac functions in a rat myocardial infarction model. J Cell Mol Med 2010.
14. Hoshi M., Williams M., Kishimoto Y. Esterification of fatty acids at room temperature by chloroform-methanolic HCl-cupric acetate. J Lipid Res 1973, 14:599-601.
15. Evans C.M., Guo L., Peterson J.J., Maccagnano-Zacher S., Krauss T.D. Ultrabright PbSe magic-sized clusters. Nano Lett 2008, 8:2896-2899.
16. Shuhendler A.J., Prasad P., Chan H.K., Gordijo C.R., Soroushian B., Kolios M., et al. Hybrid quantum dot-fatty ester stealth nanoparticles: toward clinically relevant in vivo optical imaging of deep tissue. ACS Nano 2011, 5:1958-1966.
17. Shuhendler A.J., Prasad P., Leung M., Rauth A.M., Dacosta R.S., Wu X.Y. A novel solid lipid nanoparticle formulation for active targeting to tumor alpha(v) beta(3) integrin receptors reveals cyclic RGD as a double-edged sword. Adv Healthc Mater 2012, 1:600-608.
18. Cosgrove D., Eckersley R., Blomley M., Harvey C. Quantification of blood flow. Eur Radiol 2001, 11:1338-1344.
19. Kwon S., Sevick-Muraca E.M. Noninvasive quantitative imaging of lymph function in mice. Lymphat Res Biol 2007, 5:219-231.
20. Unno N., Inuzuka K., Suzuki M., Yamamoto N., Sagara D., Nishiyama M., et al. Preliminary experience with a novel fluorescence lymphography using indocyanine green in patients with secondary lymphedema. J Vasc Surg 2007, 45:1016-1021.
21. Harrell M.I., Iritani B.M., Ruddell A. Lymph node mapping in the mouse. J Immunol Methods 2008, 332:170-174.
22. Niermann K.J., Fleischer A.C., Huamani J., Yankeelov T.E., Kim D.W., Wilson W.D., et al. Measuring tumor perfusion in control and treated murine tumors: correlation of microbubble contrast-enhanced sonography to dynamic contrast-enhanced magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. J Ultrasound Med 2007, 26:749-756.
23. Yankeelov T.E., Niermann K.J., Huamani J., Kim D.W., Quarles C.C., Fleischer A.C., et al. Correlation between estimates of tumor perfusion from microbubble contrast-enhanced sonography and dynamic contrast-enhanced magnetic resonance imaging. J Ultrasound Med 2006, 25:487-497.
24. Swartz M.A. The physiology of the lymphatic system. Adv Drug Deliv Rev 2001, 50:3-20.
25. Hojo T., Nagao T., Kikuyama M., Akashi S., Kinoshita T. Evaluation of sentinel node biopsy by combined fluorescent and dye method and lymph flow for breast cancer. Breast 2010, 19:210-213.
26. Heldin C.H., Rubin K., Pietras K., Ostman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:806-813.
27. Dreher M.R., Liu W., Michelich C.R., Dewhirst M.W., Yuan F., Chilkoti A. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006, 98:335-344.
28. Lee H., Fonge H., Hoang B., Reilly R.M., Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol Pharm 2010, 7:1195-1208.
29. Jain R.K. Determinants of tumor blood flow: a review. Cancer Res 1988, 48:2641-2658.
30. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. J Control Release 1998, 53:49-67.
31. Boucher Y., Baxter L.T., Jain R.K. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990, 50:4478-4484.